AVDL News and Press, Avadel Pharmaceuticals plc From 09/20/21

DUBLIN, Ireland, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced its support of the third annual World Narcolepsy Day on Wednesday, September 22. FT218 is the Company’s curre...

DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced t...

DUBLIN, Ireland, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announ...

Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q2 2021 Earnings Call Transcrip...

The following slide deck was published by Avadel Pharmaceuticals plc in conjunction with their 2021 Q2 earnings call. For further details see: Avadel Pharmaceuticals plc 2021 Q2 - Results - Earnings Call Presentation

Avadel Pharmaceuticals plc (AVDL) Q2 2021 Earnings Conference Call August 09, 2021, 08:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vic...

Commercial and launch preparations on track to support potential U.S. FDA approval of FT218 for the treatment of excessive daytime sleepiness and cataplexy in adults suffering from narcolepsy Presentation of post hoc analyses from pivotal REST-ON clinical trial at SLEEP 2021...

Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing. Jazz's recent lawsuit seems spurious, given how they lost to Amneal before. October PDUFA and current low prices make AVDL a compelling buy. For further details see: Avadel Pharmaceutica...

DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with nar...

DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced to...